Merck Sharp + Dohme Corp.

Zhe Wu

Jian Liu

James J Perkins

Mark E Layton

Christopher James Bungard

Ian M Bell

Ashok Arasappan

Shawn J Stachel

Jason M Cox

Christopher S Burgey

Hong Liu

Harry R Chobanian

Michael J Breslin

Kristen L G Jones

Linda M Suen-Lai

Anthony T Ginnetti

Deodial Guy Guiadeen

Michael J Kelly, Iii

Jeffrey W Schubert

Michael David VanHeyst

Akshay A Shah

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors

2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors

2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. 

2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors

Growing community of inventors

Blue Bell, PA, United States of America

Zhe Wu